Skip to main content

Table 1 Best overall response assessment by irRC simulating RECIST1.0 and irRC simulatin RECIST1.1 in 71 patients who had at least one follow-up CT

From: Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

 

Assessment by irRC simulating RECIST1.0

 

Assessment by irRC simulating RECIST1.1

irCR

irPR

irSD

irPD

 

irCR

1

1

0

0

1

irPR

0

8

1

0

10

irSD

0

0

52

1

53

irPD

0

0

1

6

7

 

1

9

54

7

71

  1. κw = 0.908 (95% CI: 0.82-0.99).